<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35724449</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0372</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current opinion in immunology</Title><ISOAbbreviation>Curr Opin Immunol</ISOAbbreviation></Journal><ArticleTitle>Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infectionImmunity and inflammaion in post-acute sequelae of SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>102228</StartPage><MedlinePgn>102228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.coi.2022.102228</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0952-7915(22)00075-9</ELocationID><Abstract><AbstractText>SARS-CoV-2 infection is known to result in a range of symptoms with varying degrees of acute-phase severity. In a subset of individuals, an equally diverse collection of long-term sequelae has been reported after convalescence. As survivorship and therefore the number of individuals with 'long-COVID' continues to grow, an understanding of the prevalence, origins, and mechanisms of post-acute sequelae manifestation is critically needed. Here, we will explore proposed roles of the anti-SARS-CoV-2 immune response in the onset, severity, and persistence of SARS-CoV-2 post-acute sequelae. We discuss the potential roles of persistent virus and autoantigens in this syndrome, as well as the contributions of unresolved inflammation and tissue injury. Furthermore, we highlight recent evidence demonstrating the potential benefits of vaccination and immunity in the resolution of post-acute symptoms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waickman</LastName><ForeName>Adam T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, United States; Institute for Global Health and Translational Science, SUNY Upstate Medical University, Syracuse, NY, United States. Electronic address: waickmaa@upstate.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Immunol</MedlineTA><NlmUniqueID>8900118</NlmUniqueID><ISSNLinking>0952-7915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35724449</ArticleId><ArticleId IdType="pmc">PMC9127180</ArticleId><ArticleId IdType="doi">10.1016/j.coi.2022.102228</ArticleId><ArticleId IdType="pii">S0952-7915(22)00075-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Bowe B., Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Systems Science and Engineering (CSSE) at Johns Hopkins University: COVID-19 Dashboard; 2022.</Citation></Reference><Reference><Citation>Tenforde M.W., Billig Rose E., Lindsell C.J., Shapiro N.I., Files D.C., Gibbs K.W., Prekker M.E., Steingrub J.S., Smithline H.A., Gong M.N., et al. Characteristics of adult outpatients and inpatients with COVID-19 &#x2014; 11 academic medical centers, United States, March&#x2013;May 2020. MMWR Morb Mortal Wkly Rep. 2020;69:841&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332092</ArticleId><ArticleId IdType="pubmed">32614810</ArticleId></ArticleIdList></Reference><Reference><Citation>Helleberg M., Niemann C.U., Moestrup K.S., Kirk O., Lebech A.-M., Lane C., Lundgren J. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222:1103&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454684</ArticleId><ArticleId IdType="pubmed">32702095</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81:e4&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., McAuley H., Harrison E.M., Shikotra A., Singapuri A., Sereno M., Elneima O., Docherty A.B., Lone N.I., Leavy O.C., et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Lu S., Tang A.F., Durstenfeld M.S., Ho H.-E., Goldberg S.A., Forman C.A., Munter S.E., Hoh R., Tai V., et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224:1839&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Tang N., Peluso M.J., Iyer N.S., Torres L., Donatelli J.L., Munter S.E., Nixon C.C., Rutishauser R.L., Rodriguez-Barraquer I., et al. Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan F.J., Hope C.M., Masavuli M.G., Lynn M.A., Mekonnen Z.A., Yeow A.E.L., Garcia-Valtanen P., Al-Delfi Z., Gummow J., Ferguson C., et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun H.J., Coutavas E., Pine A.B., Lee A.I., Yu V.L., Shallow M.K., Giovacchini C.X., Mathews A.M., Stephenson B., Que L.G., et al. Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. JCI Insight. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410030</ArticleId><ArticleId IdType="pubmed">34111030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioh F.W., Fong S.-W., Young B.E., Wu K.-X., Siau A., Krishnan S., Chan Y.-H., Carissimo G., Teo L.L., Gao F., et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987341</ArticleId><ArticleId IdType="pubmed">33752798</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquin-Proulx D., Gunn B.M., Alrubayyi A., Clark D.V., Creegan M., Kim D., Kibuuka H., Millard M., Wakabi S., Eller L.A., et al. Associations between antibody Fc-mediated effector functions and long-term sequelae in Ebola virus survivors. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8173169</ArticleId><ArticleId IdType="pubmed">34093585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann A., Foucat E., Hocini H., Lefebvre C., Hejblum B.P., Durand M., Kr&#xfc;ger M., Keita A.K., Ayouba A., M&#xe9;ly S., et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381622</ArticleId><ArticleId IdType="pubmed">32709840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschenberger M., Hunszinger V., Sparrer K.M.J. Implications of innate immunity in post-acute sequelae of non-persistent viral infections. Cells. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391718</ArticleId><ArticleId IdType="pubmed">34440903</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Guevara-Coto J., Yogendra R., Francisco E.B., Long E., Pise A., Rodrigues H., Parikh P., Mora J., Mora-Rodr&#xed;guez R.A. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.E., Feng A., Meng W., Apostolidis S.A., Mack E., Artandi M., Barman L., Bennett K., Chakraborty S., Chang I., et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P., et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y., Dorgham K., Philippot Q., Rosain J., B&#xe9;ziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregorova M., Morse D., Brignoli T., Steventon J., Hamilton F., Albur M., Arnold D., Thomas M., Halliday A., Baum H., et al. Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. eLife. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775105</ArticleId><ArticleId IdType="pubmed">33331820</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago F., Ciccarese G., Rebora A., Parodi A. Human herpesvirus-6, -7, and Epstein&#x2013;Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93:1850&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537064</ArticleId><ArticleId IdType="pubmed">32970319</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cleemput J., van Snippenberg W., Lambrechts L., Dendooven A., D&#x2019;Onofrio V., Couck L., Trypsteen W., Vanrusselt J., Theuns S., Vereecke N., et al. Organ-specific genome diversity of replication-competent SARS-CoV-2. Nat Commun. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595628</ArticleId><ArticleId IdType="pubmed">34785663</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D., Stein S., Ramelli S., Grazioli A., Chung J.-Y., Singh M., Yinda C.K., Winkler C., Dickey J., Ylaya K., et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Res Sq. 2021 doi: 10.21203/rs.3.rs-1139035/v1. pre-print (In Review)</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Tokuyama M., Cho A., Jankovic M., Schaefer-Babajew D., Oliveira T.Y., et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Richards A., Barrasa M.I., Hughes S.H., Young R.A., Jaenisch R. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci USA. 2021;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8166107</ArticleId><ArticleId IdType="pubmed">33958444</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits N., Rasmussen J., Bodea G.O., Amarilla A.A., Gerdes P., Sanchez-Luque F.J., Ajjikuttira P., Modhiran N., Liang B., Faivre J., et al. No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing. Cell Rep. 2021;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316065</ArticleId><ArticleId IdType="pubmed">34380018</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry R., Gifford R.J., Lytras S., Ray S.C., Coin L.J.M. No evidence of SARS-CoV-2 reverse transcription and integration as the origin of chimeric transcripts in patient tissues. Proc Natl Acad Sci USA. 2021;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8379926</ArticleId><ArticleId IdType="pubmed">34344759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazachenka A., Kassiotis G. SARS-CoV-2-host chimeric RNA-sequencing reads do not necessarily arise from virus integration into the host DNA. Front Microbiol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206523</ArticleId><ArticleId IdType="pubmed">34149667</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Milne A., Samms E., Stadon L., Maskell N.A., Hamilton F.W. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med. 2021;174:1334&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Files J.K., Sarkar S., Fram T.R., Boppana S., Sterrett S., Qin K., Bansal A., Long D.M., Sabbaj S., Kobie J.J., et al. Duration of post-COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses. JCI Insight. 2021;6 doi: 10.1172/jci.insight.151544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151544</ArticleId><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H., Wegman A.D., Ripich K., Friberg H., Currier J.R., Thomas S.J., Endy T.P., Waickman A.T. Persistent COVID-19 symptoms minimally impact the development of SARS-CoV-2-specific T cell immunity. Viruses. 2021;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155927</ArticleId><ArticleId IdType="pubmed">34063463</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirelli K.M., Crotty S. Germinal center enhancement by extended antigen availability. Curr Opin Immunol. 2017;47:64&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626612</ArticleId><ArticleId IdType="pubmed">28738289</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesters B.A., van Megesen K., Tomris I., de Vries R.P., Magri G., Spits H. Characterization of human FDCs reveals regulation of T cells and antigen presentation to B cells. J Exp Med. 2021;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8404474</ArticleId><ArticleId IdType="pubmed">34424268</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon M.M.L., Rybkina K., Kato Y., Kubota M., Matsumoto R., Bloom N.I., Zhang Z., Hastie K.M., Grifoni A., Weiskopf D., et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci Immunol. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626868</ArticleId><ArticleId IdType="pubmed">34618554</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C., Zurbuchen Y., Taeschler P., Ballouz T., Menges D., Hasler S., Adamo S., Raeber M.E., B&#xe4;chli E., Rudiger A., et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.S., Day A., Alsoussi W.B., Liu Z., O&#x2019;Halloran J.A., Presti R.M., Patterson B.K., Whelan S.P.J., Ellebedy A.H., Mudd P.A. SARS-CoV-2 viral RNA shedding for more than 87 days in an individual with an impaired CD8+ T cell response. Front Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820941</ArticleId><ArticleId IdType="pubmed">33488630</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., Iyer N.S., Munter S.E., Nixon C.C., Donatelli J., Thanh C., Takahashi S., Hakim J., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon I.S., Li C., Son Y.M., Goplen N.P., Wu Y., Cassmann T., Wang Z., Wei X., Tang J., Li Y., et al. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol. 2021;6 doi: 10.1126/sciimmunol.abk1741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk1741</ArticleId><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton H.J., Aye R., Idris A.H., Vistein R., Nduati E., Kai O., Mwacharo J., Li X., Gao X., Andrews T.D., et al. Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. Cell Rep. 2021;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873835</ArticleId><ArticleId IdType="pubmed">33567273</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Walker T.A., Truong A.D., Dixit A.N., Han J.E., Ramonell R.P., Runnstrom M.C., Rudolph M.E., Khosroshahi A., Lee F.E.-H., et al. Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection. MedRxiv pre-print. 2021 doi: 10.1101/2021.09.21.21263845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.21.21263845</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A., M&#xfc;ller B., Merle U. Persistent symptoms in adult patients 1 year after Coronavirus Disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2013;1198. doi: 10.1093/cid/ciab611. Apr 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella L.A., Giles J.R., Baxter A.E., Oldridge D.A., Diorio C., Kuri-Cervantes L., Alanio C., Pampena M.B., Wu J.E., Chen Z., et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci Immunol. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128303</ArticleId><ArticleId IdType="pubmed">33653907</ArticleId></ArticleIdList></Reference><Reference><Citation>Diorio C., Shraim R., Vella L.A., Giles J.R., Baxter A.E., Oldridge D.A., Canna S.W., Henrickson S.E., McNerney K.O., Balamuth F., et al. Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nat Commun. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8664884</ArticleId><ArticleId IdType="pubmed">34893640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>